02 Jul Recommended Calculation of Contraception Duration After Completion of Therapy to Minimise Risk of Embryotoxicity and Teratogenicity Associated With the Use of Halaven® (Eribulin Mesylate)
Posted at 18:10h
in
Eisai Pharmaceuticals Africa (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you about the recommended calculations of contraception duration after completion of therapy with Halaven® (eribulin mesylate), including its potential genotoxic metabolites.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
02/07/2024
File Type:
pdf
Category:
Communication To Health Care Professionals